iRadimed (NASDAQ:IRMD – Get Free Report) and Cochlear (OTCMKTS:CHEOF – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation and dividends.
Valuation and Earnings
This table compares iRadimed and Cochlear”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| iRadimed | $83.81 million | 13.29 | $22.48 million | $1.79 | 48.64 |
| Cochlear | N/A | N/A | N/A | $1.64 | 58.95 |
Dividends
iRadimed pays an annual dividend of $0.80 per share and has a dividend yield of 0.9%. Cochlear pays an annual dividend of $1.27 per share and has a dividend yield of 1.3%. iRadimed pays out 44.7% of its earnings in the form of a dividend. Cochlear pays out 77.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. iRadimed has increased its dividend for 1 consecutive years.
Analyst Ratings
This is a breakdown of recent ratings and target prices for iRadimed and Cochlear, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| iRadimed | 0 | 2 | 2 | 1 | 2.80 |
| Cochlear | 0 | 0 | 0 | 0 | 0.00 |
iRadimed currently has a consensus target price of $120.00, indicating a potential upside of 37.82%. Given iRadimed’s stronger consensus rating and higher possible upside, analysts plainly believe iRadimed is more favorable than Cochlear.
Insider and Institutional Ownership
92.3% of iRadimed shares are owned by institutional investors. Comparatively, 22.5% of Cochlear shares are owned by institutional investors. 34.6% of iRadimed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares iRadimed and Cochlear’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| iRadimed | 26.70% | 23.45% | 20.36% |
| Cochlear | N/A | N/A | N/A |
Summary
iRadimed beats Cochlear on 13 of the 15 factors compared between the two stocks.
About iRadimed
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.
About Cochlear
Cochlear Limited provides implantable hearing solutions for children and adults worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.
Receive News & Ratings for iRadimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRadimed and related companies with MarketBeat.com's FREE daily email newsletter.
